Significant Ownership of Cormorant Asset Management, LP
- Notable people
- Bihua Chen
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Cormorant Asset Management, LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager location
- Boston, MA
- Manager signature
- /s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner - By: Bihua Chen, Managing Member
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Cormorant Asset Management, LP with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Cormorant Asset Management, LP
Significant Ownership of Cormorant Asset Management, LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | Common Stock, par value $0.0001 per share | 13% | $24,434,598 | -$312,902 | 2,344,971 | -1.3% | Cormorant Asset Management, LP | 11 Dec 2025 |
| BlossomHill Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 12% | 3,615,362 | Chen Bihua | 06 Aug 2026 | ||||
| IBIO | iBio, Inc. | Common Stock, $0.001 par value per share | 10% | $7,420,347 | +$4,160,733 | 5,117,481 | +128% | Cormorant Asset Management, LP | 30 Jun 2026 |
| QNCX | Quince Therapeutics, Inc. | Common Stock, par value $0.001 per share | 10% | $1,863,500 | 108,029 | Cormorant Asset Management, LP | 30 Jun 2026 | ||
| IBIO | iBio, Inc. | Common Stock, $0.001 par value per share | 10% | 3,834,335 | Cormorant Asset Management, LP | 31 Mar 2026 | |||
| DRUG | Bright Minds Biosciences Inc. | Common Shares | 9.2% | $70,056,000 | -$3,892,000 | 900,000 | -5.3% | Cormorant Asset Management, LP | 30 Jun 2026 |
| EYPT | EyePoint, Inc. | Common Stock, par value $0.001 | 8.4% | $98,140,000 | -$17,735,300 | 7,000,000 | -15% | Cormorant Asset Management, LP | 30 Jun 2026 |
| RLYB | Rallybio Corp | Common Stock, par value $0.0001 per share | 7.6% | $232,000 | 400,000 | Cormorant Asset Management, LP | 31 Mar 2026 | ||
| CRGX | CARGO Therapeutics, Inc. | Common stock, par value $0.001 per share | 7.3% | $15,655,313 | 3,381,277 | Cormorant Asset Management, LP | 31 Mar 2025 | ||
| ANL | Adlai Nortye Ltd. | American Depositary Shares, each representing three Class A Ordinary Shares | 6.8% | $36,758,836 | +$9,982,637 | 3,978,229 | +37% | Cormorant Asset Management, LP | 30 Jun 2026 |
| CABA | Cabaletta Bio, Inc. | Common Stock, par value $0.00001 per share | 6% | $27,700,000 | -$1,385,000 | 10,000,000 | -4.8% | Cormorant Asset Management, LP | 30 Jun 2026 |
| RAPP | Rapport Therapeutics, Inc. | Common Stock, $0.001 par value per share | 5.6% | $110,738,900 | -$12,501,000 | 2,657,521 | -10% | Cormorant Asset Management, LP | 30 Jun 2026 |
| BIOA | BioAge Labs, Inc. | Common Stock, par value $0.00001 per share | 5.4% | $59,382,628 | -$12,420,000 | 2,390,605 | -17% | Cormorant Asset Management, LP | 30 Jun 2026 |
| AGMB | Agomab Therapeutics NV | American Depositary Shares, each representing one common share, no nominal value per share | 5% | $25,171,203 | 2,465,348 | Cormorant Asset Management, LP | 31 Mar 2026 | ||
| MLTX | MoonLake Immunotherapeutics | Class A ordinary share, par value $0.0001 per share | 4.4% | $65,262,616 | -$25,959,000 | 3,205,433 | -28% | Cormorant Asset Management, LP | 30 Jun 2026 |
| PRAX | Praxis Precision Medicines, Inc. | Common Stock, par value $0.0001 per share | 4% | $53,000,000 | -$33,125,000 | 1,000,000 | -38% | Cormorant Asset Management, LP | 30 Sep 2025 |
| BMEA | Biomea Fusion, Inc. | Common Stock | 1.5% | $2,143,436 | -$5,295,734 | 1,060,792 | -71% | Chen Bihua | 22 Oct 2025 |
| VYNE | VYNE Therapeutics Inc. | Common Stock, par value $0.0001 per share | 0% | $0 | -$459,264 | 0 | -100% | Cormorant Asset Management, LP | 30 Sep 2025 |
| ENGN | enGene Holdings Inc. | Common Shares | 0% | $0 | -$27,040,000 | 0 | -100% | Cormorant Asset Management, LP | 31 Mar 2026 |
| OKUR | OnKure Therapeutics, Inc. | Class A Common Stock, par value $0.0001 per share | 0% | $0 | 0 | Cormorant Asset Management, LP | 15 May 2025 | ||
| KALA | KALA BIO, Inc. | Common Stock, $0.001 par value per share | 0% | $0 | -$931,568 | 0 | -100% | Cormorant Asset Management, LP | 30 Sep 2025 |
| RLYB | Rallybio Corp | Common Stock, par value $0.0001 per share | 0% | $0 | 0 | Cormorant Asset Management, LP | 30 Jun 2026 |
Schedules 13D/G Reported by Cormorant Asset Management, LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.